Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

16 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of CTCF binding sites through CUT&RUN sequencing in the neuroblastoma cell line CLB-GA.

ABSTRACT: CUT&RUN sequencing to define binding sites for CTCF and IgG in the neuroblastoma cell line CLB-GA.

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Homo sapiens

SUBMITTER: Sarah-Lee Bekaert

PROVIDER: E-MTAB-12586 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Identification of SOX11 binding sites through CUT&RUN sequencing in the neuroblastoma cell lines IMR-32, CLB-GA, NGP and SH-EP

Project description:CUT&RUN sequencing to define binding sites for SOX11 and IgG in the neuroblastoma cell lines IMR-32, CLB-GA and NGP as well as neuroblastoma cell line SH-EP after SOX11 overexpression for 48h. A SOX11 inducible overexpression system was generated using a Tet-on system.

2022-12-13 | E-MTAB-11905 | biostudies-arrayexpress

ATAC-seq in IMR-32, CLB-GA and SH-EP neuroblastoma cell lines.

Project description:ATAC-seq to define open and closed chromatin in the human IMR-32, CLB-GA and SH-EP neuroblastoma cell lines in an untreated way.

2023-02-23 | E-MTAB-12588 | biostudies-arrayexpress

RNA-seq of CLB-GA neuroblastoma cell line upon TBX2 knockdown

Project description:RNA-seq upon TBX2 knockdown in the neuroblastoma cell line CLB-GA. Cells were transduced with two different shRNAs (sh#2 and sh#4) targeting TBX2 and a non-targeting control (NTC), and selected with puromycin. Analysis was performed seven days upon TBX2 knockdown, including three biological replicates per condition.

2018-08-16 | E-MTAB-6567 | biostudies-arrayexpress

Single cell RNA-Seq of Neuroblastoma cell line (CLB-berlud)

Project description:We report the application of single-molecule-based sequencing technology for high-throughput profiling of Neuroblastoma cell line (CLB-berlud) Examination of gene expression in Neuroblastoma cell line (CLB-berlud), as a negative control

2020-02-14 | GSE130022 | GEO

RNA-seq of CLB-GA neuroblastoma cell line treated with Celastrol against DMSO treated controls

Project description:RNA-seq upon Celastrol (200 nM) treatment in the neuroblastoma cell line CLB-GA. Analysis was performed 48h upon treatment. Four biological replicates per condition.

2021-07-01 | E-MTAB-9315 | biostudies-arrayexpress

Trypanosoma cruzi CLB vs Trypanosoma rangeli and Trypanosoma conorhini

Project description:Comparative genomic analysis of T. cruzi CLB vs Trypanosoma rangeli (strains SC, Choachí, C23, H14, R1625 and PIT10) and Trypanosoma conorhini

2023-04-11 | GSE229354 | GEO

4C sequencing for the SOX11 promoter in the neuroblastoma cell lines CLB-GA, KELLY, SK-N-AS and SH-EP

Project description:4C sequencing for the SOX11 promoter in the neuroblastoma cell lines CLB-GA, KELLY, SK-N-AS and SH-EP.

2023-02-19 | E-MTAB-12580 | biostudies-arrayexpress

Brd4, H3K27Ac, and H3K36me3 binding profiles with or without Dinaciclib in human neuroblastoma CLB-GA cells

Project description:Promoter rearrangement of the telomerase reverse transcriptase (TERT) gene juxtaposes the coding sequence to strong enhancer elements, leading to TERT overexpression and poor prognosis. TERT associated oncogenic signaling in neuroblastoma remains unclear. Gene set enrichment analysis of RNA-seq data from 498 neuroblastoma patients revealed a coordinated activation of oncogenic signaling pathways and differentially overexpressed gene signature in a subgroup of MycN non-amplified neuroblastomas with TERT overexpression. ChIP-seq analysis of human neuroblastoma cell line CLB-GA harboring TERT rearrangement uncovered genome-wide chromatin co-occupancy of Brd4 and H3K27Ac and robust enrichment of H3K36me3 in TERT and multiple TERT-associated genes. We demonstrated a critical regulatory role of Brd4 and cyclin-dependent kinases in the expression and chromatin activation. Inhibition of both with AZD5153 and dinaciclib proved most effective in tumor growth suppression of neuroblastoma cell lines, primary cells, and xenograft. Our study provides a therapeutic strategy utilizing epigenetic targeting of neuroblastoma with TERT overexpression.

2020-05-12 | GSE133453 | GEO

RNA-seq of human CLB-GA and NGP neuroblastoma cell lines with SOX11 knockdown as compared to control

Project description:RNA-seq upon SOX11 knockdown in the neuroblastoma cell lines CLB-GA and NGP. Cells were nucleofected with a pool of four different siRNAs targeting SOX11 and a non-targeting control (NTC). Analysis was performed 2 days upon SOX11 knockdown, including four biological replicates per condition.

2022-12-13 | E-MTAB-11883 | biostudies-arrayexpress

expression profiling data of CLB-GA neuroblastoma cells upon TAE-684, Crizotinib, X-396, LDK378, Trametinib, BEZ-235 and Vandetanib

Project description:Treatment of the CLB-GA cell line with complementary ALK, MEK, PI3K/mTOR or RET inhibitors (and DMSO (VWR) as control) was performed in duplicate for each drug using the GI50 concentrations (see further): 0.5M-k_M Crizotinib (Pfizer/Sigma-Aldrich); 0.06M-k_M X-396 (VWR); 0.2M-k_M LDK378 (Hoelzel Biotech); 0.05uM Trametinib (SelleckChem); 0.5M-k_M BEZ-235 (SelleckChem); 9.5M-k_M Vandetanib (SelleckChem). Cells were collected at 6h following treatment and further profiled. The selected inhibitor concentrations were used based on determined GI50 values. For generation of gene expression time series following ALK inhibition, CLB-GA cells were treated with 0.3uM TAE-684 (and DMSO as control treatment) and RNA was harvested at 0 M-^IM-[M-R 10M-^IM-[M-* M-^IM-[M-R 30M-^IM-[M-* M-^IM-[M-R 60M-^IM-[M-* M-^IM-[M-R 120M-^IM-[M-* M-^IM-[M-R 240M-^IM-[M-* M-^IM-[M-R 360M-^IM-[M-* time points. Samples were labeled and hybridised to the Sureprint G3 human GE or G3 Mouse GE 8x60K microarrays (Agilent Technologies), according to the manufacturerM-^IM-[M-*s guidelines and starting from 200 ng of RNA.

2015-05-04 | E-MTAB-3206 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data